Skip to main content
. 2020 Jun 4;21(11):4026. doi: 10.3390/ijms21114026

Figure 3.

Figure 3

Cell cycle analysis—short-term treatment of synchronized cells with 0.5 nM everolimus (E) or 2.5 µM sulforaphane (S) or 0.5 nM everolimus+2.5 µM sulforaphane (E + S). Untreated cells served as controls (C). Percentage of RT112, UMUC3, or TCCSUP cells in G0/G1, S and G2/M-phase is indicated. Inter-assay variation <10%, intra-assay variation <40%.